Biotech Values

[DewDiligence]

Rebif delays conversion from CIS to MS in phase-3 study:

http://www.merck.de/en/media/extNewsDetail.html?newsId=BE4AD7B22B3C0C39C12577C600734F7D&newsType=1

The primary endpoint was time to conversion. For patients in the thrice-weekly dosing arm (44mcg per dose), HR=0.49 and p<0.00001. For patients in the once-weekly dosing arm (also 44mcg per dose), HR=0.69 and p=0.008. The full dataset will be presented at an unspecified medical conference.

Copaxone is already approved in this indication based on pivotal data broadly similar to the above data for Rebif (#msg-55641123).